Ypsomed announced today that it selected Samuel Künzli to take over the company’s chief financial officer (CFO) position.
Niklaus Ramseier elected to hand over the reins to the CFO position after more than 20 years in the post. The transition begins on March 31, 2024, with Ramseier remaining available to the drug delivery device maker for strategic projects. Künzli begins as CFO on April 1, 2024.
Ramseier joined the Burgdorf, Switzerland-based company in 2002 as CFO. From then, he led the finance and controlling department at Ypsomed. He also took charge of the company’s IT department until midway through last year. At the end of March 2024, he departs the CFO position and his spot as a member of the executive board.
He will remain available on a reduced basis for strategic projects until his early retirement in January 2025.
Künzli spent the last three years as CFO at Feintool Group. He previously worked for Stadler for eight years in various financial management roles.
“Niklaus Ramseier has accompanied our company for more than two decades with a lot of expertise and great commitment as CFO. Thanks to his competence and reliability, we were able to master numerous challenges in the past and successfully prepare the company for the continued growth phase,” said Ypsomed CEO Simon Michel. “We thank Niklaus Ramseier for his valuable contributions to the company and are pleased that he is available to us for the further transformation.
“At the same time, I am pleased that we were able to win Samuel Künzli, a proven financial expert with capital market experience, as his successor. I am convinced that Samuel Künzli will optimally support the execution of our strategy. We give him a warm welcome.”